This research demonstrates bis-thiadiazole sulfonamides inhibiting Alzheimer enzymes AChE and BuChE, suggesting potential new treatments.
In this research work, bis-thiadiazole based sulfonamide hybrid analogues (1-15) were synthesized by a novel synthetic approach. Structural confirmation was accomplished through 1HNMR, 13CNMR, and HREI-MS techniques. Further, these analogues were examined for their biological activities against AChE and BuChE (Alzheimer disease). These compounds have a diverse range of potency against targeted enzymes with inhibitory concentration ranges for AChE (2.80 ± 0.30-21.10 ± 0.10 μM) and for BuChE (3.20 ± 0.10-22.40 ± 0.70 μM), respectively. Compounds 4, 9, and 11 emerged as the potent compounds against targeted enzymes and have inhibitory concentrations lower than donepezil (IC50 = 5.50 ± 0.10 and 6.10 ± 0.20 μM) used as a reference drug. In addition, versatile computational approaches were adopted to determine interactive properties (by molecular docking), electronic distribution and stability (through DFT calculations), and drug likeness characteristics (by ADMET predictions) of the synthesized potent scaffolds. Product confirmation was confirmed by thin layer chromatography.
No takes yet. Share an insight, caveat, or question.
Ullah et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: